ストックスクリーナーアプリを入手
3.75
5.54%
-0.22
前日終値:
$3.97
開ける：
$4.01
24時間の取引高:
2.29M
Relative Volume:
1.48
時価総額：
$559.06M
収益：
$181.41M
当期純損益:
$-59.56M
株価収益率:
-8.9286
EPS:
-0.42
ネットキャッシュフロー:
$-38.83M
1週間 パフォーマンス:
+4.46%
1か月 パフォーマンス:
+12.28%
6か月 パフォーマンス:
+32.04%
1年 パフォーマンス:
+25.00%
1日の値動き範囲:
$3.69
$4.0103
1週間の範囲:
$3.5599
$4.10
52週間の値動き範囲:
$1.69
$4.10
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
3.75 | 559.06M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Still a Buy? - Defense World
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month HighStill a Buy? - MarketBeat
Xeris Pharmaceuticals stock hits 52-week high of $3.87 - Investing.com India
Xeris Pharmaceuticals stock hits 52-week high of $3.87 By Investing.com - Investing.com South Africa
Legato Capital Management LLC Purchases Shares of 142,164 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Raised by Janney Montgomery Scott LLC - Defense World
Take off with Xeris Biopharma Holdings Inc (XERS): Get ready for trading - SETE News
Xeris Biopharma Holdings Inc [XERS] Shares Fall -1.36 % on Thursday - Knox Daily
Omnicell, Inc [OMCL] Records 50-Day SMA of $44.59 - Knox Daily
Stock Performance Spotlight: Xeris Biopharma Holdings Inc (XERS) Ends the Day at 3.64, Up by 1.39 - The Dwinnex
Xeris to Participate in Upcoming Investor Conferences - BioSpace
A year in review: Xeris Biopharma Holdings Inc (XERS)’s performance in the last year - US Post News
SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Perhaps timely catching Xeris Biopharma Holdings Inc (XERS) would be a good idea - SETE News
Piper Sandler downgrades Xeris Biopharma Holdings Inc (XERS) rating to a Neutral - Knox Daily
Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio - Simply Wall St
JPMorgan Chase & Co. Acquires 67,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Down -1.47% This Year: What To Expect Next - Stocks Register
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness - Beloit Daily News
ADA Partners With Xeris to Combat Rising Diabetes Emergency Cases Amid 202,000 Annual ER Visits - StockTitan
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than -103.7% - Stocks Register
Barclays PLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M - MSN
Arecor stock plummets after Tetris retreat - Business Weekly
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7%Here's Why - MarketBeat
Xeris Expects to Exceed Full-Year 2024 Financial Guidance - BioSpace
Xeris Biopharma exceeds 2024 revenue guidance - Investing.com India
Xeris Biopharma Exceeds 2024 Guidance with $203M Revenue, Posts Record Q4 Growth - StockTitan
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Position Lifted by Principal Financial Group Inc. - Defense World
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 6, 2025 - BioSpace
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Geode Capital Management LLC - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Jane Street Group LLC - Defense World
Barclays PLC Purchases 151,685 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
State Street Corp Sells 53,915 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - The Manila Times
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2%What's Next? - MarketBeat
Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Walleye Capital LLC Purchases Shares of 1,121,738 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $237,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
XERS (Xeris Biopharma Holdings) Revenue : $187.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Xeris Biopharma Holdings (FRA:2B30) Other Long Term Assets : €4.9 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Stockholders Equity : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) EPS (Diluted) : $-0.44 (TTM As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) GF Score : 75/100 (As of Nov. 26, 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Accounts Payable : $7.5 Mil (As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference - Business Wire
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
Xeris Biopharma Holdings Inc (XERS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Aug 12 '24 |
Buy |
2.25 |
4,515 |
10,147 |
25,200 |
| Schmid John P. | Director |
Aug 09 '24 |
Buy |
2.37 |
4,285 |
10,134 |
20,685 |
| Schmid John P. | Director |
May 10 '24 |
Buy |
1.91 |
5,400 |
10,314 |
16,400 |
| JOHNSON JOHN | Director |
Mar 18 '24 |
Option Exercise |
1.99 |
215,600 |
429,044 |
751,412 |
| Schmid John P. | Director |
Mar 14 '24 |
Buy |
2.16 |
4,500 |
9,720 |
11,000 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):